Alexander G. Hajduczok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander G. Hajduczok has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Devin Stives
Aurora Cardiovascular and Thoracic Services, Aurora St. Luke's Medical Center, Milwaukee, WI
3 shared publications- Ami L. DeWaters
Ami L. DeWaters, MD, MSc, is an Associate Professor of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA
2 shared publications - Andrew Tinsley
Department of Medicine, Division of Gastroenterology and Hepatology, Pennsylvania State University College of Medicine, Hershey, USA
2 shared publications - Audrey K Thorp
Division of Internal Medicine, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States
2 shared publications - Brinnae Bent
Duke University
2 shared publications - Catharine I. Paules
Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania (C.I.P.)
2 shared publications
Latest Publications
- 18 September 2026
- Published by Elsevier in Journal of Cardiac Failure
JCF In Case You Missed It! Summary of European Society of Cardiology (ESC) Congress 2026
- 18 September 2026
- Published by Elsevier in Journal of Cardiac Failure
JCF In Case You Missed It! Summary of European Society of Cardiology (ESC) Congress 2026
- 2 July 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (7) , e013065
Association Between Neighborhood Opportunity With Exercise-Related Cardiac Symptoms and ECG Abnormalities in US Youth Athletes
BACKGROUND: Sudden cardiac arrest disproportionately affects youths from lower socioeconomic neighborhoods, yet the mechanisms of this disparity in youth athletes remain unclear. METHODS: We retrospectively analyzed the HeartBytes National Youth Cardiac Registry (Simon’s Heart, a US nonprofit for sudden cardiac death prevention), in which youth athletes aged P <0.001). After multivariable adjustment, participants in the very high child opportunity index quintile had lower odds of exercise-related chest pain (adjusted odds ratio, 0.45 [95% CI, 0.32–0.63]), exercise-related fatigue (adjusted odds ratio, 0.65 [95% CI, 0.47–0.87]), and abnormal ECGs (adjusted odds ratio, 0.58 [95% CI, 0.42–0.82]) relative to the very low quintile. CONCLUSIONS: Youth athletes from lower-opportunity neighborhoods were underrepresented in preparticipation screening and demonstrated higher prevalence and adjusted odds of exercise-related cardiac symptoms and ECG abnormalities. Prospective longitudinal studies are needed to determine clinical significance and inform equitable screening strategies.
- 2 July 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (7) , e013065
Association Between Neighborhood Opportunity With Exercise-Related Cardiac Symptoms and ECG Abnormalities in US Youth Athletes
BACKGROUND: Sudden cardiac arrest disproportionately affects youths from lower socioeconomic neighborhoods, yet the mechanisms of this disparity in youth athletes remain unclear. METHODS: We retrospectively analyzed the HeartBytes National Youth Cardiac Registry (Simon’s Heart, a US nonprofit for sudden cardiac death prevention), in which youth athletes aged P <0.001). After multivariable adjustment, participants in the very high child opportunity index quintile had lower odds of exercise-related chest pain (adjusted odds ratio, 0.45 [95% CI, 0.32–0.63]), exercise-related fatigue (adjusted odds ratio, 0.65 [95% CI, 0.47–0.87]), and abnormal ECGs (adjusted odds ratio, 0.58 [95% CI, 0.42–0.82]) relative to the very low quintile. CONCLUSIONS: Youth athletes from lower-opportunity neighborhoods were underrepresented in preparticipation screening and demonstrated higher prevalence and adjusted odds of exercise-related cardiac symptoms and ECG abnormalities. Prospective longitudinal studies are needed to determine clinical significance and inform equitable screening strategies.
- 1 May 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (6) , 1095-1100
In Case You Missed It: Technology and Heart Failure Therapeutics 2026
- 1 May 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (6) , 1095-1100
In Case You Missed It: Technology and Heart Failure Therapeutics 2026
- 20 April 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (7) , 1068-1071
Reimagining Heart Failure Care: Highlights from ACC 2025
- 20 April 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (7) , 1068-1071
Reimagining Heart Failure Care: Highlights from ACC 2025
- 28 November 2024
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (4) , 717-720
Windy City Breakthroughs: Highlights from the American Heart Association Scientific Sessions 2024
- 28 November 2024
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (4) , 717-720
Windy City Breakthroughs: Highlights from the American Heart Association Scientific Sessions 2024
- Top Cited PapersOpen Access
- 27 May 2024
- Published by MDPI AG in Journal of Functional Morphology and Kinesiology
- Vol. 9 (2) , 93
Heart Rate Variability Applications in Strength and Conditioning: A Narrative Review
Heart rate variability (HRV) is defined as the fluctuation of time intervals between adjacent heartbeats and is commonly used as a surrogate measure of autonomic function. HRV has become an increasingly measured variable by wearable technology for use in fitness and sport applications. However, with its increased use, a gap has arisen between the research and the application of this technology in strength and conditioning. The goal of this narrative literature review is to discuss current evidence and propose preliminary guidelines regarding the application of HRV in strength and conditioning. A literature review was conducted searching for HRV and strength and conditioning, aiming to focus on studies with time-domain measurements. Studies suggest that HRV is a helpful metric to assess training status, adaptability, and recovery after a training program. Although reduced HRV may be a sign of overreaching and/or overtraining syndrome, it may not be a sensitive marker in aerobic-trained athletes and therefore has different utilities for different athletic populations. There is likely utility to HRV-guided programming compared to predefined programming in several types of training. Evidence-based preliminary guidelines for the application of HRV in strength and conditioning are discussed. This is an evolving area of research, and more data are needed to evaluate the best practices for applying HRV in strength and conditioning.
- 27 May 2024
- Published by MDPI AG in Journal of Functional Morphology and Kinesiology
- Vol. 9 (2) , 93
Top Cited PapersOpen AccessHeart Rate Variability Applications in Strength and Conditioning: A Narrative Review
Heart rate variability (HRV) is defined as the fluctuation of time intervals between adjacent heartbeats and is commonly used as a surrogate measure of autonomic function. HRV has become an increasingly measured variable by wearable technology for use in fitness and sport applications. However, with its increased use, a gap has arisen between the research and the application of this technology in strength and conditioning. The goal of this narrative literature review is to discuss current evidence and propose preliminary guidelines regarding the application of HRV in strength and conditioning. A literature review was conducted searching for HRV and strength and conditioning, aiming to focus on studies with time-domain measurements. Studies suggest that HRV is a helpful metric to assess training status, adaptability, and recovery after a training program. Although reduced HRV may be a sign of overreaching and/or overtraining syndrome, it may not be a sensitive marker in aerobic-trained athletes and therefore has different utilities for different athletic populations. There is likely utility to HRV-guided programming compared to predefined programming in several types of training. Evidence-based preliminary guidelines for the application of HRV in strength and conditioning are discussed. This is an evolving area of research, and more data are needed to evaluate the best practices for applying HRV in strength and conditioning.
- Open Access
- 5 September 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 6 (9) , ytac362
Recurrent giant cell myocarditis after heart transplant: a case report
Giant cell myocarditis (GCM) is a rare but well-known cause of fulminant myocarditis. Despite optimal medical therapy, many patients progress to orthotopic heart transplant (OHT). We present a case of recurrent GCM following OHT, including complex considerations in patient management and infectious sequelae. A 33-year-old previously healthy male presented with 2 months of worsening shortness of breath. Transthoracic echocardiogram (TTE) demonstrated a left ventricular ejection fraction of 30–35%. After ruling out an ischaemic aetiology, he was discharged on guideline-directed medical therapy and later presented with productive cough, worsening dyspnoea on exertion, and diarrhoea. He was found to have elevated troponins and N-terminal pro-brain natriuretic peptide, lactic acidosis, progression of severe bi-ventricular dysfunction on TTE and right heart catheterization, and low cardiac index (1.0 L/min/m2) requiring inotropes. He then required left ventricular assist device as a bridge to OHT. Pathology of the apical core diagnosed GCM as the cause of his fulminant heart failure. He eventually underwent heart transplantation, which was complicated by recurrent GCM. Treatment required intensification of his immunosuppressive regimen, which led to multiple infectious sequelae including norovirus, Shiga-like toxin producing Escherichia coli, and disseminated nocardia of the lung and brain. As of the most recent follow-up, the patient is currently clinically stable. Although recurrent GCM after OHT has been reported in the literature, the prognosis is not well understood and there are no clear guidelines regarding management. This case summarizes clinical considerations, treatment strategies, and adverse effects of recurrent GCM treatment.
- 5 September 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 6 (9) , ytac362
Open AccessRecurrent giant cell myocarditis after heart transplant: a case report
Giant cell myocarditis (GCM) is a rare but well-known cause of fulminant myocarditis. Despite optimal medical therapy, many patients progress to orthotopic heart transplant (OHT). We present a case of recurrent GCM following OHT, including complex considerations in patient management and infectious sequelae. A 33-year-old previously healthy male presented with 2 months of worsening shortness of breath. Transthoracic echocardiogram (TTE) demonstrated a left ventricular ejection fraction of 30–35%. After ruling out an ischaemic aetiology, he was discharged on guideline-directed medical therapy and later presented with productive cough, worsening dyspnoea on exertion, and diarrhoea. He was found to have elevated troponins and N-terminal pro-brain natriuretic peptide, lactic acidosis, progression of severe bi-ventricular dysfunction on TTE and right heart catheterization, and low cardiac index (1.0 L/min/m2) requiring inotropes. He then required left ventricular assist device as a bridge to OHT. Pathology of the apical core diagnosed GCM as the cause of his fulminant heart failure. He eventually underwent heart transplantation, which was complicated by recurrent GCM. Treatment required intensification of his immunosuppressive regimen, which led to multiple infectious sequelae including norovirus, Shiga-like toxin producing Escherichia coli, and disseminated nocardia of the lung and brain. As of the most recent follow-up, the patient is currently clinically stable. Although recurrent GCM after OHT has been reported in the literature, the prognosis is not well understood and there are no clear guidelines regarding management. This case summarizes clinical considerations, treatment strategies, and adverse effects of recurrent GCM treatment.